1	AVE8062	AVE8062	B-NP	NN	O	9	NMOD	-1
2	:	:	O	:	O	1	P	-1
3	a	a	B-NP	DT	O	9	NMOD	-1
4	new	new	I-NP	JJ	O	9	NMOD	-1
5	combretastatin	combretastatin	I-NP	NN	O	9	NMOD	-1
6	derivative	derivative	I-NP	JJ	O	9	NMOD	-1
7	vascular	vascular	I-NP	JJ	O	9	NMOD	-1
8	disrupting	disrupting	I-NP	NN	O	9	NMOD	6	disrupting
9	agent	agent	I-NP	NN	O	0	ROOT	-1
10	.	.	O	.	O	9	P	-1

1	Angiogenesis	Angiogenesis	B-NP	NN	O	2	SUB	3	Angiogenesis
2	has	have	B-VP	VBZ	O	14	VMOD	-1
3	an	an	B-NP	DT	O	5	NMOD	-1
4	essential	essential	I-NP	JJ	O	5	NMOD	0
5	role	role	I-NP	NN	O	2	OBJ	0
6	in	in	B-PP	IN	O	2	VMOD	-1
7	promoting	promote	B-VP	VBG	O	6	PMOD	17	promoting
8	and	and	I-VP	CC	O	7	VMOD	-1
9	supporting	support	I-VP	VBG	O	7	VC	17	supporting
10	tumor	tumor	B-NP	NN	O	11	NMOD	-1
11	growth	growth	I-NP	NN	O	9	OBJ	4	growth
12	and	and	O	CC	O	14	VMOD	-1
13	it	it	B-NP	PRP	O	14	SUB	-1
14	is	be	B-VP	VBZ	O	0	ROOT	-1
15	an	an	B-NP	DT	O	18	NMOD	-1
16	important	important	I-NP	JJ	O	17	AMOD	0
17	therapeutic	therapeutic	I-NP	JJ	O	18	NMOD	-1
18	target	target	I-NP	NN	O	14	PRD	0
19	.	.	O	.	O	14	P	-1

1	The	The	B-NP	DT	O	4	NMOD	-1
2	tumor	tumor	I-NP	NN	O	4	NMOD	-1
3	vascular	vascular	I-NP	JJ	O	4	NMOD	-1
4	network	network	I-NP	NN	O	5	SUB	-1
5	is	be	B-VP	VBZ	O	0	ROOT	-1
6	the	the	B-NP	DT	O	7	NMOD	-1
7	result	result	I-NP	NN	O	5	PRD	-1
8	of	of	B-PP	IN	O	7	NMOD	-1
9	pro-angiogenic	pro-angiogenic	B-NP	JJ	O	11	AMOD	3	angiogenic
10	and	and	I-NP	CC	O	11	AMOD	-1
11	inhibitory	inhibitory	I-NP	JJ	B-protein	12	NMOD	0
12	factors	factor	I-NP	NNS	I-protein	8	PMOD	-1
13	as	as	B-CONJP	RB	O	12	NMOD	-1
14	well	well	I-CONJP	RB	O	13	DEP	-1
15	as	as	I-CONJP	IN	O	13	DEP	-1
16	of	of	B-PP	IN	O	13	PMOD	-1
17	the	the	B-NP	DT	O	18	NMOD	-1
18	interaction	interaction	I-NP	NN	O	16	PMOD	15	interaction
19	between	between	B-PP	IN	O	18	NMOD	-1
20	endothelial	endothelial	B-NP	JJ	B-cell_type	21	NMOD	-1
21	cells	cell	I-NP	NNS	I-cell_type	24	NMOD	-1
22	and	and	O	CC	O	24	NMOD	-1
23	extracellular	extracellular	B-NP	JJ	O	24	NMOD	-1
24	matrix	matrix	I-NP	NN	O	19	PMOD	-1
25	.	.	O	.	O	5	P	-1

1	Different	Different	B-NP	JJ	O	3	NMOD	-1
2	antiangiogenic	antiangiogenic	I-NP	JJ	O	3	NMOD	3	angiogenic
3	therapeutics	therapeutic	I-NP	NNS	O	4	SUB	-1
4	have	have	B-VP	VBP	O	0	ROOT	-1
5	been	be	I-VP	VBN	O	4	VC	-1
6	developed	develop	I-VP	VBN	O	5	VC	0
7	to	to	I-VP	TO	O	8	VMOD	-1
8	improve	improve	I-VP	VB	O	6	VMOD	17	improve
9	tumor	tumor	B-NP	NN	O	10	NMOD	-1
10	control	control	I-NP	NN	O	8	OBJ	16	control
11	through	through	B-PP	IN	O	8	VMOD	0
12	vascular-targeting	vascular-targeting	B-NP	JJ	O	13	NMOD	-1
13	agents	agent	I-NP	NNS	O	11	PMOD	-1
14	(	(	O	(	O	16	DEP	-1
15	VTA	VTA	B-NP	NN	B-protein	16	DEP	-1
16	)	)	O	)	O	13	NMOD	-1
17	.	.	O	.	O	4	P	-1

1	VTAs	VTA	B-NP	NNS	B-protein	2	SUB	-1
2	can	can	B-VP	MD	O	0	ROOT	-1
3	be	be	I-VP	VB	O	2	VC	-1
4	divided	divide	I-VP	VBN	O	3	VC	-1
5	into	into	B-PP	IN	O	4	VMOD	-1
6	two	two	B-NP	CD	O	7	NMOD	-1
7	groups	group	I-NP	NNS	O	5	PMOD	-1
8	:	:	O	:	O	2	P	-1
9	antiangiogenic	antiangiogenic	B-NP	JJ	O	10	NMOD	3	angiogenic
10	agents	agent	I-NP	NNS	O	13	NMOD	-1
11	and	and	O	CC	O	13	NMOD	-1
12	vascular-disrupting	vascular-disrupting	B-NP	JJ	O	13	NMOD	-1
13	agents	agent	I-NP	NNS	O	2	VMOD	-1
14	(	(	O	(	O	16	DEP	-1
15	VDAs	VDA	B-NP	NNS	B-protein	16	DEP	-1
16	)	)	O	)	O	13	NMOD	-1
17	.	.	O	.	O	2	P	-1

1	VTAs	VTA	B-NP	NNS	B-protein	2	SUB	-1
2	inhibit	inhibit	B-VP	VBP	O	0	ROOT	0
3	specific	specific	B-NP	JJ	B-protein	4	NMOD	-1
4	factors	factor	I-NP	NNS	I-protein	2	OBJ	-1
5	required	require	B-VP	VBN	O	4	NMOD	0
6	to	to	B-VP	TO	O	7	VMOD	-1
7	induce	induce	I-VP	VB	O	5	VMOD	0
8	and	and	I-VP	CC	O	7	VMOD	-1
9	direct	direct	I-VP	VB	O	7	VMOD	-1
10	the	the	B-NP	DT	O	12	NMOD	-1
11	angiogenic	angiogenic	I-NP	JJ	O	12	NMOD	3	angiogenic
12	process	process	I-NP	NN	O	9	OBJ	-1
13	,	,	O	,	O	2	P	-1
14	with	with	B-PP	IN	O	2	VMOD	-1
15	major	major	B-NP	JJ	O	16	NMOD	-1
16	activity	activity	I-NP	NN	O	14	PMOD	0
17	against	against	B-PP	IN	O	16	NMOD	0
18	small	small	B-NP	JJ	O	20	NMOD	-1
19	tumor	tumor	I-NP	NN	O	20	NMOD	-1
20	masses	mass	I-NP	NNS	O	17	PMOD	-1
21	and	and	B-PP	CC	O	14	PMOD	-1
22	at	at	B-PP	IN	O	14	PMOD	-1
23	the	the	B-NP	DT	O	25	NMOD	-1
24	tumor	tumor	I-NP	NN	O	25	NMOD	-1
25	periphery	periphery	I-NP	NN	O	22	PMOD	-1
26	,	,	O	,	O	2	P	-1
27	encompassing	encompass	B-VP	VBG	O	2	VMOD	-1
28	monoclonal	monoclonal	B-NP	JJ	B-protein	29	NMOD	-1
29	antibodies	antibody	I-NP	NNS	I-protein	33	NMOD	-1
30	and	and	O	CC	O	32	NMOD	-1
31	small	small	B-NP	JJ	O	32	NMOD	-1
32	molecules	molecule	I-NP	NNS	O	33	NMOD	-1
33	inhibitors	inhibitor	I-NP	NNS	O	27	OBJ	-1
34	of	of	B-PP	IN	O	33	NMOD	-1
35	the	the	B-NP	DT	O	38	NMOD	-1
36	tyrosine	tyrosine	I-NP	NN	B-protein	38	NMOD	-1
37	kinase	kinase	I-NP	NN	I-protein	38	NMOD	-1
38	domain	domain	I-NP	NN	I-protein	34	PMOD	-1
39	of	of	B-PP	IN	O	38	NMOD	-1
40	the	the	B-NP	DT	O	42	NMOD	-1
41	VEGF	VEGF	I-NP	NN	B-protein	42	NMOD	-1
42	receptor	receptor	I-NP	NN	I-protein	39	PMOD	-1
43	.	.	O	.	O	2	P	-1

1	VDAs	VDA	B-NP	NNS	B-protein	3	SUB	-1
2	specifically	specifically	B-ADVP	RB	O	3	VMOD	-1
3	target	target	B-VP	VBP	O	0	ROOT	16	target
4	and	and	I-VP	CC	O	3	VMOD	-1
5	destroy	destroy	I-VP	VBP	O	3	VMOD	18	destroy
6	well-established	well-established	B-NP	JJ	O	8	NMOD	2	established
7	tumor	tumor	I-NP	NN	O	8	NMOD	-1
8	vessels	vessel	I-NP	NNS	O	5	OBJ	-1
9	with	with	B-PP	IN	O	8	NMOD	-1
10	ischemia	ischemia	B-NP	NN	O	12	NMOD	-1
11	and	and	I-NP	CC	O	12	NMOD	-1
12	destruction	destruction	I-NP	NN	O	9	PMOD	6	destruction
13	of	of	B-PP	IN	O	12	NMOD	-1
14	large	large	B-NP	JJ	O	15	NMOD	-1
15	masses	mass	I-NP	NNS	O	13	PMOD	-1
16	with	with	B-PP	IN	O	15	NMOD	-1
17	central	central	B-NP	JJ	O	19	NMOD	-1
18	hemorrhagic	hemorrhagic	I-NP	JJ	O	19	NMOD	-1
19	necrosis	necrosis	I-NP	NN	O	21	NMOD	5	necrosis
20	and	and	I-NP	CC	O	21	NMOD	-1
21	survival	survival	I-NP	NN	O	16	PMOD	5	survival
22	of	of	B-PP	IN	O	21	NMOD	-1
23	a	a	B-NP	DT	O	27	NMOD	-1
24	thin	thin	I-NP	JJ	O	27	NMOD	-1
25	peripheral	peripheral	I-NP	JJ	O	27	NMOD	-1
26	tumor	tumor	I-NP	NN	O	27	NMOD	-1
27	layer	layer	I-NP	NN	O	22	PMOD	-1
28	.	.	O	.	O	3	P	-1

1	VDAs	VDA	B-NP	NNS	B-protein	2	SUB	-1
2	can	can	B-VP	MD	O	0	ROOT	-1
3	be	be	I-VP	VB	O	2	VC	-1
4	divided	divide	I-VP	VBN	O	3	VC	-1
5	into	into	B-PP	IN	O	4	VMOD	-1
6	biologics	biologic	B-NP	NNS	O	5	PMOD	-1
7	,	,	O	,	O	6	P	-1
8	such	such	B-PP	JJ	O	9	PMOD	-1
9	as	as	I-PP	IN	O	6	NMOD	-1
10	ligand-based	ligand-based	B-ADJP	JJ	O	14	NMOD	-1
11	,	,	O	,	O	14	P	-1
12	and	and	O	CC	O	14	NMOD	-1
13	small-molecule	small-molecule	B-NP	JJ	O	14	NMOD	-1
14	agents	agent	I-NP	NNS	O	9	PMOD	-1
15	;	;	O	:	O	2	P	-1
16	this	this	B-NP	DT	O	18	NMOD	-1
17	second	second	I-NP	JJ	O	18	NMOD	-1
18	group	group	I-NP	NN	O	19	SUB	-1
19	includes	include	B-VP	VBZ	O	2	VMOD	-1
20	small-molecule	small-molecule	B-NP	JJ	B-protein	21	NMOD	-1
21	VDAs	VDA	I-NP	NNS	I-protein	19	OBJ	-1
22	like	like	B-PP	IN	O	21	NMOD	-1
23	flavonoids	flavonoid	B-NP	NNS	O	37	NMOD	-1
24	,	,	O	,	O	23	P	-1
25	such	such	B-PP	JJ	O	26	PMOD	-1
26	as	as	I-PP	IN	O	23	NMOD	-1
27	5	5	B-NP	CD	O	26	AMOD	-1
28	,	,	O	,	O	37	P	-1
29	6-dimethylxanthenone-4-acetic	6-dimethylxanthenone-4-acetic	B-NP	JJ	O	30	NMOD	-1
30	acid	acid	I-NP	NN	O	37	NMOD	-1
31	(	(	O	(	O	33	DEP	-1
32	DMXAA	DMXAA	B-NP	NN	B-protein	33	DEP	-1
33	)	)	O	)	O	30	NMOD	-1
34	,	,	O	,	O	37	P	-1
35	and	and	O	CC	O	37	NMOD	-1
36	microtubule-destabilizing	microtubule-destabilizing	B-NP	JJ	O	37	NMOD	-1
37	agents	agent	I-NP	NNS	O	22	PMOD	-1
38	.	.	O	.	O	2	P	-1

1	In	In	B-PP	IN	O	5	VMOD	-1
2	this	this	B-NP	DT	O	3	NMOD	-1
3	review	review	I-NP	NN	O	1	PMOD	-1
4	we	we	B-NP	PRP	O	5	SUB	-1
5	will	will	B-VP	MD	O	0	ROOT	-1
6	discuss	discuss	I-VP	VB	O	5	VC	-1
7	the	the	B-NP	DT	O	8	NMOD	-1
8	mechanism	mechanism	I-NP	NN	O	19	NMOD	0
9	of	of	B-PP	IN	O	8	NMOD	-1
10	action	action	B-NP	NN	O	9	PMOD	0
11	,	,	O	,	O	19	P	-1
12	as	as	B-CONJP	RB	O	19	NMOD	-1
13	well	well	I-CONJP	RB	O	12	DEP	-1
14	as	as	I-CONJP	IN	O	12	DEP	-1
15	the	the	B-NP	DT	O	19	NMOD	-1
16	preclinical	preclinical	I-NP	JJ	O	18	AMOD	-1
17	and	and	I-NP	CC	O	18	AMOD	-1
18	clinical	clinical	I-NP	JJ	O	19	NMOD	-1
19	results	result	I-NP	NNS	O	6	OBJ	0
20	,	,	O	,	O	19	P	-1
21	of	of	B-PP	IN	O	19	NMOD	-1
22	one	one	B-NP	CD	O	21	PMOD	-1
23	of	of	B-PP	IN	O	22	NMOD	-1
24	the	the	B-NP	DT	O	28	NMOD	-1
25	most	most	I-NP	RBS	O	26	AMOD	-1
26	promising	promising	I-NP	JJ	O	28	NMOD	-1
27	antitubulin	antitubulin	I-NP	JJ	O	28	NMOD	-1
28	agents	agent	I-NP	NNS	O	23	PMOD	-1
29	:	:	O	:	O	5	P	-1
30	the	the	B-NP	DT	O	33	NMOD	-1
31	combretastatin	combretastatin	I-NP	NN	O	33	NMOD	-1
32	A4-phosphate	A4-phosphate	I-NP	NN	O	33	NMOD	-1
33	derivative	derivative	I-NP	NN	O	35	NMOD	-1
34	,	,	O	,	O	35	P	-1
35	AVE8062A	AVE8062A	B-NP	NN	O	5	VMOD	-1
36	.	.	O	.	O	5	P	-1

